| 000 | 01155 a2200301 4500 | ||
|---|---|---|---|
| 005 | 20250516145613.0 | ||
| 264 | 0 | _c20130905 | |
| 008 | 201309s 0 0 eng d | ||
| 022 | _a1938-3673 | ||
| 024 | 7 |
_a10.1189/jlb.1212621 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aIntlekofer, Andrew M | |
| 245 | 0 | 0 |
_aAt the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. _h[electronic resource] |
| 260 |
_bJournal of leukocyte biology _cJul 2013 |
||
| 300 |
_a25-39 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Review | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntibodies, Blocking _xtherapeutic use |
| 650 | 0 | 4 |
_aCTLA-4 Antigen _xantagonists & inhibitors |
| 650 | 0 | 4 | _aDrug Evaluation, Preclinical |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunotherapy |
| 650 | 0 | 4 |
_aNeoplasms _ximmunology |
| 650 | 0 | 4 |
_aProgrammed Cell Death 1 Receptor _xantagonists & inhibitors |
| 700 | 1 | _aThompson, Craig B | |
| 773 | 0 |
_tJournal of leukocyte biology _gvol. 94 _gno. 1 _gp. 25-39 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1189/jlb.1212621 _zAvailable from publisher's website |
| 999 |
_c22706937 _d22706937 |
||